What we suspected all along is confirmed for the first time I'm aware of
in print:
"These data suggest that trastuzumab radically changes the natural history of HER2-positive metastatic breast cancer. While women with HER2-positive tumors have historically been thought to have a worse prognosis, the advent of trastuzumab means that they appear to do far better in response to chemotherapy than do patients with HER2-negative tumors, exhibiting higher rates of response, longer durations of treatment, and improved overall survival. Thus, HER2-negative and HER2-positive tumors remain clinically distinct, and it is not fair to say that HER2-negative outcomes are equivalent to HER2-positive outcomes in patients also receiving trastuzumab."
For those who want to read the whole article:
http://www.medscape.com/viewarticle/466393
Finally, we're out of the dungeon; kind of like the tortoise and the rabbit wouldn't you say?
Regards,
Al
Threaded Mode